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CS7I3L/6Jmicc were injected with D-amphctamine sulfate for 
the last six days of gestation. Their offspring were compared with 
those of saline -injected and untreated controls. Although the amphet-
amine -treated mothers gained less weight than controls during treat-
ment and three days post partum, this did not affect litter size or 
body or brain weight of the offspring at birth. Injections of either 
drug or saline altered the rate of weight gain for the first month. 
The offspring of the a.mphetamine-treated mothers had lower 
levels of brain norepinephrine on the day of birth and higher levels of 
norepinephrine and dopamine than either control group on day 30. 
Their open field activity was higher than either control group on 
day 22, but jiggle platform activity was lower than saline controls 
at all times studied. The catecholamine levels of saline -injected 
controls were higher than those of untreated controls at days 21 and 
30. 
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INTRODUCTION 
Amphetamines are popular members of the current drug scene, 
being used by both young people and adults. They have been implicated 
in creating a paranoid and delusional state during which acts of pe rsonal 
violence are cOnlm.itted (4) and in being causally associated with con-
genital heart disease when used during pregnancy (71). Methylamphet-
amines have been im.plicated in the development of necrotizing angiitis 
in adults (25). The Food and Drug Adrn.inistration has recently re-
stricted use of arnphetarn.ines to treatment of narcolepsy, hyperkinetic 
children, and exogenous obesity as a short term. (few weeks) adjunct 
for weight control (3). 
The mode of action of amphetamine in the brain has been 
studied in adult organisms. A.mphetaITline effects are m.ediated 
through effects on the adrenergic synapses I i. e., those involving 
the neurotransmitters dopamine (DA) and norepinephrine (NE) (43, 
51, 101). 
The parent amino acids 'for catecholatnine formation are 
phenylalanine and tyrosine.. Phenylalanine is para-hydroxylated 
to form L-tyrosine (Fig. I.). Tyrosine is meta-hydroxylated in the 
presence of oxygen, tetrahydrobiopterin, NADPH, and the enzyme 
2 
Figure I. The Metabolism. of Tyrosine. Tyrosine is metabolized to 
dopa.rnine and norepinephrine. These catecholam.ines are in turn 
converted to their m.ethoxy metabolites via COMT. 
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tyrosine hydroxylase to foral 3, 4-dihydroxyphenylalanine (L-DOPA). 
Dopa decarboxylase, in the presence of pyridoxal phosphate and hy-
drogen ions, will convert DOPA to DA. DA can be S -hydroxylated to 
form NE by the relatively nonspecific enzym.e doparnine- S -hydroxylase. 
This enzyITle requires ascorbic acid, fUlUaric acid, and oxygen for 
activity. Doparn.ine - S -hydroxylase is bound to the rnelUbranes of the 
catecholaITline storage vesicles (421 44, 101, 105 1 116). 
In the conversion of tyrosine to L-DOPA, tyrosine hydroxylase 
is subject to feedback inhibition by elevated levels of NE (63). There 
is also some secondary control of NE formation at the level of 
dopamine- S-hydroxylase (113). 
The catecholarrlines are m.etabolized intraneuronally by 
monoamine oxidase (MAO), a m.itochondrial enzyrn.e that deaminates 
the catecholam.ines. Another enzynle, catechol-O-methyl transferase 
(COMT), is present primarily in the extraneuronal space and 
O-m.ethylates the active catecholamines in the lTIeta position (II, 42, 
83, 116). 
DA and NE are localized in specific areas of the brain. The 
principal brain DA tract at least partially originates in the pars corn.pacta 
of the substantia nigra with nerve terminals in the corpus striatum., a 
brain region as sociated with motor coordination (5, 16, 32, 37, 54, 78, 
91, 99). The ventrolTIedial nucleus _0£ the hypothalamus is rich in DA 
terminals also and is implicated in gonadotropic levels and food intake 
(54 ). 
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A large part of the NE in the cerebral helTIispheres and dien-
cephalon is derived from neurons corning from or passing through the 
lTIcscncephalon. The ITlajor NE tracts in the brain have their perikarya 
in the brain steITl with axons ascending via the median forebrain bundle. 
These tracts have nerve endings throughout the brain. The highest con-
centration of NE is in the hypothalarnus and the limbic system. (5, 16, 
23, 27, 54, 74, 78, 91). 
In adult rats the NE levels of the hypothalamus average about 
1.75 lJg/g with the rem.ainder of the brain areas showing lesser 
aITlounts. The corpus striatum contains approxirnatel y 5 lJg / g of DA, 
the highest level of this monoam.ine in any brain area. Adult mice have 
about.3 lJg/g of NE and. 7 lJg/g of DA in the whole brain (16, 19" 21, 
67, 74, 81, Ill). A wide range of values has been reported for both 
rats and mice. The species of the animal and the analytical rnethod 
used could be responsible for these variations in tissue levels. For 
all species studied" however, the relative amounts of catecholarnines 
in various areas of the brain are consistent. 
NE and DA levels in the m.ouse and rat brain are initially low 
and gradually increase with age. In rats 12 days of age, there are 
• J5J Wg of NE per whole brain. By 24 clays of age there arc. 397 
lJg and. 510 lJg of NE and DA, respectively, per whole brain ·(88). 
In mice the level of NE reaches adult values by approximately 30 days 
of age. Adult levels of DA are not obtained in the mouse brain until 
much later (1). 
A number of studies have been aimed at determining a relation-
ship between the levels of DA and NE and the behavior of experimental 
animals. DA seems to be involved in stereotyped behavior (35, 55, 79, 
80, 87, 91, 114) and possibly in hypermotility (9, 106). 
Stereotypy in rats and mice consists of licking, sniffing, biting 
cage bars, and backward locomotion at times, or sitting with hunched 
backs. Forward locomotion, eating, and grooming are absent (37). 
In humans stereotyped behavior consists of normal movements, such 
as arm rubbing or leg swinging, continued for prolonged periods (91, 
III ). 
When reserpine is given to animals, brain NE and DA are 
depleted. Even with the MAO inhibitor nialamide, NE, normet-
anephrine, DA, and 3-0-methyl dopamine are undetectable. When 
amphetamine (10 mg/kg) is given after the reserpine and nialamide, 
levels of 3 -O-methyl dopamine increase to measurable amounts and 
characteristic stereotypy is observed (79). This same dose of D-
or L-amphetamine sulfate injected subcutaneously 1 hour before 
intraventricular injection of 3H - DA brings about no change in the 
endogenous DA levels in the corpus striatum, but the uptake of 3H-DA 
is lowered. Stereotypy is again observed (112). 
DA injected iontophoretically into the area of the caudate 
nucleus will cause spike rate depression or facilitation in those 
caudate neurons in which depression is produced by electrical stim-
ulation of the substantia nigra (84). Bilateral intrastriatal micro-
5 
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inj<:ctions of l)A or p-hyc1roxyamphetarninc lead to stereotyped behavior. 
Injections of NE into the same areas have no effect (37). Elevated 
levels of brain DA can aid in protection against audiogenic seizures 
in mice (19). The involveITlent of DA systems in stereotyped behavior 
in hUITlans is illustrated by the prevention of such behavior by 
haloperidol in Gilles de la Tourette's disease and by some side 
effects of L-DOPA used an antiparkinsonian agent (91, Ill). 
NE is thought to be involved in locomotion and aggres sive 
behavior (79, 101, 106, 117). NE that is released by reserpine is 
inactivated by MAO inside the neuron (58). There is an increase in 
3 -ITlethoxynorepinepherine .metabolites with neurotransrnis sion or 
electrical stiITlulation involving NE pathways (61). Amphetamine 
administration results in a decrease in endogenous NE levels and an 
increase in methylated metabolites of NE and DA (10, 94, 112). 
Arnphetarnine may work by MAO inhibition (12, 18, 43, 83), 
direct receptor action (89), synaptic release of NE and DA (51, 94), 
~ 
inhibition of catecholamine reuptake (42, 51, 83, 94, 112), and/or 
inhibition of dopaITline - S -hydroxylase (43). Work done using a, -methyl 
tyrosine ( a, -MT) or H44/68, inhibitors of tyrosine hydroxylase; FLA-
63, inhibitor of dopamine- B -hydroxylase; and reserpine have shown 
that amphetamine is dependent on a continued biosynthesis of the 
catechola:mines for action. At low doses of amphetamine ( <1 m.g/kg) 
the stores may be able to supply the catecholamines for activity (101, 
104, 119). Levels of brain NE increase with low doses of amphetamine, 
probably due to the release of feedback inhibition of tyrosine hydrox-
ylase (61). 
It has been reported the D-arnphetarnine antagonizes the effect 
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of a-MT in a stimulus dependent situation by retarding the decline of 
brain catecholarnines (70, 84, 114). Recent work has shown that DA 
present in the predominately NE areas of the brain is used for NE 
synthesis. Antagonism of the effect of a-MT may be due to a 
conversion of the DA present in the noradrenergic neurons to NE with 
a subsequent initial decrease in the DA levels followed later by a 
lowering of NE levels (113). 
When a.mphetarnine is administered to an organism, it is 
metabolized 9Y oxidative deamination OJ lJY.Qr~~....ftJjY.JJJlfJ~~) 
(90). Amphetamine is taken up and concentrated in the brain very 
rapidly in cOITlparison with other tissues (12, 22). It is possible 
that amphetamine can not be taken up into the dense core vesicles , 
which contain dopamine- ~ -hydroxylase, but must be p-hydroxylated 
to p-hydroxyarnphetamine first (100). It is known that p-hydroxylation 
precedes B -hydroxylation in biological material (22, 46, 90, 105). 
Para-hydroxyarnphetamine and its glucuronide can be excreted by the 
organism Or the p-hydroxyarnphetam.ine can be taken up by the dense 
core vesicles and rapidly converted to p-hydroxynorephedrine by 
dopamine- S -hydroxylase. Para-hydroxynorephedrine remains in 
the tissues for longer periods than amphetamine indicating that it can 
be incorporated into the storage granules (46). Para-hydroxynorephedrine, 
Figure II. The Hydroxylation of AITlphetamine. A.mphetaITline is 
hydroxylated first in the para position and then in the S position to 
form. the false neurotransITlitte r p -hydroxynorephedrine. Norephe-
drine is not formed in vivo. 
( 0 >r~H2 -crH-CH ) • (0 )-rH-1H-CH3 
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like NE, can be depleted froIn the dense core vesicles with successive 
doses of amphcta:minc or by reserpine (22). A:mphetarnine disappears 
from the brain in about 16 hours. Para-hydroxynorephedrine is still 
present 48 hours after a single dose of amphetam.ine (S rng/kg). The 
sustained decline of NE from the brain is due to the form.ation and 
storage of p-hydroxynorephedrine in the dense core vesicles (10, 22, 
46, 105). 
Stein and Wise (95, 96, 97 t 98) have found an increase in the 
methylated NE metabolites in the hypothalamus and am.ygdala follow-
ing rewarding m.edial forebrain bundle stimulation. Amphetamine 
(3 mg/kg) caused an increase in the labeling of the amygdaloid 
perfusate following intraventricular injection of 3H - NE but no increase 
in the hypothalamic perfusate, unlike rewarding stimulation. A 3-fold 
increase in radioactivity did occur in the hypothalamic perfusate when 
14C_DOPA was used with amphetamine. 
Behaviorally in adults, amphetamine increases lnotor activity 
(motility) as .measured by an ANIMEX activity detector (63, 106). A 
dose response curve of locomotor activity was observed in an activity 
cage using photocells for detectors. There was progressive enhance-
ment of locomotor activity as measured by this type activity box up to 
1.5 mg/kg of D-amphetamine with decreasing locomotion and increas-
ing stereotypy beyond this dosage (112). Dextro-amphetamine sulfate, 
S mg/kg, causes a decline in brain NE levels and a slight increase in 
brain DA levels in adults. Behaviorally this dose of amphetamine 
9 
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produces locomotor activity at about 500/0 of the maximally effective dos e. 
This is also the EDSO for com.pulsive gnawing behavior (23, 89, Ill). 
Olds (72) reported the effect in rats of several stimulatory drugs 
on food consu.mption and instrumental responding (bar-pressing) for 
food. An1phctalninc treated anirnals ingested the same arn.ount of food 
as nornlals but responded at higher rates for food reward and for longer 
tilncs during extinction of the response. 
Alpha-rn.ethyl tyrosine lowers endogenous levels of brain NE. 
Six hours after a single a. -MT injection the response rate on a con-
tinuous avoidance task was greatly reduced. Following chronic treat-
ment a rat functions normally on the task. Arn.phetam.ine given to a 
rat chronically pretreated with a-MT causes a decrease in levels of 
continuous avoidance. This is possibly explained in terms of denerva-
tion hypersensitivity in that the animal readjusts to these new, lowered 
levels of NE. The NE released by the amphetamine would lower the 
endogenous levels to the point that depression would follow (67). 
The biochemical and behavioral changes noted using amphetamine 
could seem to imply some corollary between the two parameters. Pre-
natal stress in the form of maternal foot-shock (53), handling (13, 30), 
undernutrition (2, 88), and drug and monoamine ad.ministration (15, 26, 
41, 45, 86, 121) has been shown to induce both short term and prolonged 
changes in catecholamine levels and/or activity in the young organism. 
Coyle and Axelrod (31) have recently shown th~t in the brain the NE uptake 
mechanism and the initial increase in the endogenous NE level occur on 
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the seventeenth and eighteenth days of gestation, respectively. Amphet-
amine given during the last 6 days of pregnancy in the mouse could 
affect either or both of the newly developing proces sese 
The reserpine sensitive catecholamine s·::orage ITlechanism be-
COInes functional after birth and increases with time (31). If the 
initiation of catecholam.ine storage is dependent on early NE uptake, 
early alterations in uptake or endogenous catecholamine levels could 
lead to modified levels at later times. 
It was the purpose of this investigation to determine whether 
administration of 5 rng/kg of D-am.phetamine sulfate, a dosage having 
the biochemical and behavioral effects previously described, during 
the last 6 days of gestation would produce modifications in the NE and 
DA levels and generalized m.otor activity in the offspring. Corellations 
between brain catecholamine levels and behavior were studied. 
MATERIALS AND METHODS 
Experimental Procedure - Pregnant C57BL/6J mice (The Jackson Lab-
oratory, Bar Harbor, Maine) were divided into three groups: exper-
. imental, saline control, and untreated control. All animals were 
housed in separate plastic cages with regular mouse chow and water 
ad libitum. Each mouse was weighed daily during the last 6 days of 
pregnancy_ The experimental group was injected daily with 5 mg/kg 
of D-amphetamine sulfate (Smith, Kline. and French) in a 1 mg/ml 
• 90/0 saline solution. The saline control mice were injected with 
5 ml/kg of .90/0 saline. The untreated controls received no injections. 
The drug or vehicle was given intraperitoneally using a standard 
1 ml tuberculin syringe between 10:00 a. m. and 12:00 noon each day. 
The injections were discontinued on delivery with the last 
injection approximately 18 hours before delivery. The mothers were 
weighed until weaning of the pups at 21 days of age. 
Litters were sexed and culled to six pups, note bei~g made of 
any dead, discolored, or malformed pups. The pups were weighed 
daily until sacrificed. 
Food and water intake for each cage was recorded beginning with 
the first injection day and continuing through sacrifice of the pups. 
The pups were sacrificed at 0, 3, 7 t 14, 21, and 30 days of 
age. When possible the O-day sarrlple consisted of 6 brains, the 
3 -day sarrlple used 5, the 7 -day used 3, and the 14-day had 2 brains 
per saITlple. The others were made of 1 brain per sample. After 
decapitation the brain from the base of the m.edulla oblongata and 
minus the olfactory bulbs was rapidly removed~ weighted, and placed 
on ice. The brains were placed in labelled vials and stored in a 
-180 C freezer until used for catecholamine as says. Freezing for 
up to 2 weeks had no effect on catecholamine levels when kept at this 
temperature (Table I, Appendix). 
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Preparation of the Alumina - The method of Anton and Sayre (6) was 
followed for the acti vatio n of the aluminum oxide. One -hundred grams 
of aluminum. oxide (Woelm Neutral Activity Grade I) in 500 Inl of 
2 N hydrochloric acid (Hel) in a covered liter beaker were stirred 
and heated to 90-100° C for 45 minutes. The suspension was removed 
from the heat and allowed to settle for 1~ minutes. The yellow super-
natant and finer alulTIinum oxide particles were removed by aspiration. 
The remaining alumina was washed twice with 250 rol of 2 N HCl at 
70° C for 10 minutes. The supernatant and finer particles were 
discarded. The alumina was washed about 25 times with 200 ml 
portions of deionized water until a pH of 3.4 was reached. The su-
pernatant and finer particles were discarded after each wash. After 
the last wash, the aluminum oxide was transferred to an evaporating 
o 0 
dish and heated for 1 hour at 120 C, 2 hours at 200 C, and then 
o stored at 37 c. 
Saluple Preparation - Samples we re prepared by the method of Anton 
and Sayre (6) with modifications by Boggan>:~. Brains were removed 
from the freezer and allowed to thaw for 2 minutes. The tissue was 
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homogenized in 20 ml of cold 0.4 N perchloric acid (peA) in a Potter-
ElvchjCITl homogenizer with a Teflon pestle using 5 strokes at a pestle 
speed of 8 as marked on a Tri-R Stir-R motor. The hO}nogenate was 
transferred to a cold 30 ml Corex tube and centrifuged in a Sorvall 
SS-34 rotor at 30,000 x g for 15 minutes at 4 0 C. The supernatant 
could be stored for several hours or frozen for at least 24 hours if 
the procedure could not be continued immediately. 
To a 100 ml beaker for each sample was added 400 mg of 
activated alurrlinurn oxide and 5 ml of deionized water containing 
200 mg disodium ethylenediamine tetra-acetate (EDTA) and 10 mg 
sodiulTI-rrleta-bisulfite freshly prepared. The beakers were kept on 
Ice. The cold sample was added "to each beaker just before neutralizing. 
Norepinephrine base (Sigma), 1.5 ng and 1 ng of dopamine base (Sigma) 
in 20 rnl of 0.4 N peA were also added to one beaker to check for re-
covery. The samples were adjusted to pH 8.6 using 2 N Tris. 
Samples were stirred with a 6-unit m.ulti-stirrer in 4 sample units. 
~:(,w. O. Boggan 1970: personal com.munication. 
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The 4 rnicroelectrodes were connected to a Beckman Digital pH meter 
o 
set at 15 C. After reaching pH 8. 6 the samples were stirred for 5 
minutes. Use of magnetic stirrers caused grinding of the alumina. 
After 5 minutes the samples were removed and placed on ice 
until all the samples were neutralized. 
The supernatant was aspirated and the alumina was washed into 
15 ml culture tubes witb scre'W-on t-ops using 1 D L221 of deionized W"at-er. 
The tubes were shaken On a rotary stirrer at a speed of 2 for 2 minutes. 
The tubes were then removed, tapped gently on the bottom and sides, 
and allowed to settle for 3 minutes. The water was aspirated and 
discarded and the washing was repeated 3 times. 
The catecholarnines were eluted in 3 ml of 0.05 N peA by 
shaking at high speed for 15 minutes on an Eberbach shaker. 
Catecholamine Assays - For the NE assay 0.3 ml of 0.5 M phosphate 
buffer (adjust aIM solution of KH2P04 to pH 7.0 using 1 N sodium 
hydroxide (NaOH) and dilute with deionized water to O. 5 M) was added 
to a 13 x 100 mm test tube for each sample. A 0.6 ml aliquot of each 
sample was transferred to the appropriate tube of buffer and shaken 
welL A 0.6 rnl aliquot of 0.05 N peA was also added to a tube for 
the blank. The Perkin-Elmer spectrofluorometer was adjusted to 80 
using Fluorescein, 150 ng/ml, at a sensitivity of 3, activation slit of 5, 
ernis sion slit of 16, activation wave length of 410 nm, and emis sion 
wave length of 520 nrn. The remainder of the solutions were then 
prepared (see below) and the assay continued. 
16 
To the sample-buffer mixture was added 0.06 ml of freshly pre-
pared 0.25 0/ 0 potassium ferricyanide and the solution was stirred on a 
Vortex mixer. After 1 minute, oxidation was stopped with the addition 
of 0.6 ml of freshly prepared alkaline ascorbate (dissolve 100 m.g of 
ascorbic acid in 1 ml of deionized water, add 0.2 rnl of this solution 
to 10 ml of 10 N NaOH, and stir thoroughly). After stirring water, 
0.5 ml, was added to prevent crystallization and mixed thoroughly. 
Samples were read immediately. 
A standard curve was prepared initially by setting the inst.:u-
ment to 80 as described, then running 4 samples at each 100, 200, 
and 400 ng of NE base/O. 6 ml of 0.05 N peA. The averages of these 
concentration assays gave a linear plot extending through zero and 
having a sensitivity of 1.9 ng. Sample values with the blank sub-
tracted were read from this plot. The NE recovery averaged 750/0. 
The DA assay was similar to the NE assay. Two-tenths ml 
of 0.5 M phosphate buffer (as described for the NE assay) was added 
to a 13 x 100 rom test tube for each sample. A 0.4 ml aliquot of each 
sample and 0.4 rol aliquot of O. 05 N peA for the blank were added to 
the appropriate test tube and stirred. The spectrofluorometer was 
adjusted to 80 using 20 II M quinin~ sulfate J sensitivity of 1, activation 
slit of 5, emission slit of 14) activation wave length of 335 nrn, and an 
emission wave length of 390 nIne To the buffer-sample mixture was 
added O. 04 ml freshly prepared O. 50/0 sodium periodate (make in a 
volumetric flask) and mixed on the Vortex mixer. One minute later, 
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0.2 rn.l of freshly prepared alkaline sulfite (dissolve 125 m.g anhydrous 
NaZS03 in 0.5 ml of water, add 4. 5 rnl of 5 N NaOH and m.ix thoroughly) 
was added and rnixed on the Vortex. Water, O.56rnl, 0.2 rnl of 0.5 M 
citrate buffer (adjust a solution of 1.0 M citric acid to pH 4.0 with 
10 N NaOH and dilute to 0.5 M with water), and 0.34 rnl of 3 M 
phosphoric acid (make daily) were added and tnixed by shaking on the 
Vortex. Samples were read im.m.ediately. 
A standard curve was prepared as for the NE. The standards 
were prepared in terms of the free base. A sensitivity of 8 ng was 
obtained. The DA recovery averaged 600/0. 
Psychological Studies - For the psychological studies the litters were 
culled at delivery to 4 pups, 2 m.ales and 2 females where possible. 
On days 12, 15, 18, 21, and 30, two pups frorn each litter 
were tested for five minutes on a Lehigh Valley Electronics jiggle 
platform enclosed by a 22 x 18 x 12 dark, soundproof box. The mouse 
was placed in a cylindrical plastic container 5. 5 inches high and 7. 75 
inches across. The saIne two pups were used on each testing day and 
were distinguished by ear punching the right ear on day 12. The 
activity counts were recorded for each minute of the total five minute 
testing tim.e. The plastic container was dried and cleaned of any 
fecal boli after each m.ouse. The mice were tested between 9:00 a. m. 
and 12:00 noon of the testing days. 
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On days 13, 16, 19, 221 and 31 the pups used on the jiggle plat-
for.m were tested in a 16 x 16 x 4 inch open field activity box. The box 
was ITlarked off into 4 x 4 inch squares and a lTIouse was counted as 
entering a square if he placed two feet across the line marking a 
square. A plexiglass cover was used to prevent the mouse froITl jump-
ing onto the sides or out of the box. The mouse was observed for 5 
Ininutes with the number of squares entered per Ininute recorded. 
The weights of the mothe r until weaning at day 21 and the 
weights of the individual pups was recorded from day 0 through day 
3 O. 
RESULTS 
Results are presented for the am.phetamine (DAMS), saline 
control (SC), and untreated control (UC) groups. Two types of 
statistical analyses were used: the two-tailed t-test and a least 
squares analysis using a modified~:~ BMDX64 program from the UCLA 
Biomedical Co.mputer Program.s run on an IBM 360/40 cOnlputer. 
The least squares analysis compared, where applicable, group, 
tiITle, and sex effects. The pattern of change over time by the groups 
(group by time), group changes according to sex (group by sex), and 
changes over time according to sex (time by sex) were also determined 
by this analysis. 
Maternal Weights - Table I. presents data for the weights of the mothers 
from the start of the injections to delivery. There was a statistically 
significant difference (p < .05) in the body weight of the DAMS females 
beginning 4 days before delivery (D-4). D-3 showed no statistical weight 
difference but the mean for the DAMS was lower than that of either the 
';-C or the SC groups. The weight difference continued for at least 3 
da" s post partum (Table II. ). 
,roO 
'f·e . B. Loadholt 1971: personal communication. 
Table I. Maternal Weights in GraITls from the Beginning of Injections to 
Delivery (BiochclUical Study). Mean ITlaternal weights in grams are 
given for a.mphetarnine (DAMS), saline (SC), and untreated (UC) groups. 
The DAMS ITlothers received a daily injection of 5 mg/kg of D-amphet-
amine sulfate beginning 6 days prior to delivery (D-6) and continuing 
through delivery. The SC animals received 5 ml/kg of .90/0 saline 
daily during the same period. The DC mothers received no injections 
during pregnancy. The litters of these animals were culled to 6 pups 
and were used for the biochemical studies. 
Treatment DAMS SC UC 
Day 
D-6 26.6+1.4 27.3+1.8 27.8+3.1 
D-5 27.3+1.7 28.5+1.9 28.7+3.7 
D-4 28. 4+2. O~:~ 30.2+2. 2 30.4+4.0 
D-3 29.8+1.9 31.9+2.0 32.3+4.3 
D-2 31. 2+2. 2;::c 33.6+2.2 34.2+4.5 
D-l 32. 8+3. O;::~ 34.8+2.6 36.0+4.4 
Delivery 23.7+2.1 24. 6 + 1. 7 24.7+2.2 
N = 14 N = 16 N = 11 
Mean + S. D. M. 
Table III jVfaternal Weights in Grams from the Beginning of Injections 
to Delivery (Biochemical Study). 
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Table II. Maternal Weights in Gram.s from. Delivery to Weaning of the 
Pups at 21 Days (Biochemical Study). Mean m.aternal weights in grams 
are given for DAMS, SC, and DC groups for 3-21 days post partum. 
These are the same animals described in Table I. 
21a 
Treatment DAMS SC DC 
Day 
Delivery 23.7+2.1(14) 24.6+1.7(16) 24.7+2.2(11) 
"I" 
3 24.4+2.1""(10) 25.9+1.9(13) 26.8+2.6(10) 
7 27.3+1.0(7) 27.4+2.1(10) 28.2+2.9(7) 
14 30.4+1.3(5) 29.4+3.5(6) 30. 9+2. 5(6) 
21 26.9+1.1(5) 26. 7+2. 4(6) 28.9+2.1(4} 
"I" 
Mean + S. D. M. (N) ""(p < • 0 5) 
Table II. Maternal Weights in Gram.s from Delivery to Weaning of 
the Pups at 21 Days (Biochemical Study). 
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Although the DAMS mothers gained less weight during pregnancy, 
the litter size was not affected by the drug or vehicle ad:tninistrations. 
DAMS averaged 6.4 + 1.8 pups per litter, the SC group litter consisted 
of an average 6.7 + 2.1 pups and the DC group averaged 6.6 + 2. 1 pups 
per litter. These litter sizes are not significantly different. 
The weights of the mothers of the pups used in the psychological 
studies were recorded separately to check for any maternal weight 
changes resulting from. the handling of the pups (Table III. ). No 
weight difference was noted between drug and control groups of mothers 
nor was there a difference between the maternal weights of the bio-
chernical group and the psychological group. 
Food and Water Consum.ption - Food and water consumption per day 
per cage per gram m.aternai'weight was obtained beginning with the 
initial treatment day and continuing through weaning of the pups 
(Table IV.). The weight of the pups was not us ed ip these calculations. 
It was believed the pups did not consume food pellets and water until 
their eyes opened and even then the amount was not appreciable 
considering the lack of weight change for the pups for one or two days 
after weaning and low food and water consumption per pup at the same 
tin'lc. There was no statistically significant difference between either 
of the three groups using the two-tailed t-test. Thus, even though the 
DAMS animals gained less weight, the food and water consumption per 
gram was equivalent to the other two groups. 
Table III. Maternal Weights in Grams from Day 12 Through Day 21 
(Psychological Study). The body weights of the mothers of the pups 
used in the psychological testing showed no group differences or group 
by tim.e interactions. No differences in body weight were noted between 
the ITlothers in the psychological study and the mothers in the bio-
chemical study. 
23a 
Group DAMS SC DC 
Day 
12 28.3+1.4 28.4+1.9 28.1+1.7 -
13 28.8+1.4 28.0+2.2 28.2+1.6 - -
14 29.5+1.3 28.7+1.3 28.6+1. 5 
15 28.4+1.6 28.2+1.3 27.8+1.3 
16 28.8+2.1 28.1+1.7 27.2+1.0 
17 3 o. 1 +2. 6 27.5+1.5 28.1+1.7 
18 28.5+2.4 27.5+1.5 27.4+1.1 
19 27.5+2.7 26.7+1.5 27.2+0.8 
20 27. 9+2. 3 26.0+1.5 27.1+0.7 
21 27.1+2.2 25.9+1.5 26.2+1.3 
N"= 6 N = 5 N = 6 
Mean + S. D. M. 
Table III. Maternal Weights in Gram.s from. Day 12 Through Day 21 
(Psychological Study). 
Table IV. Food and Water Consum.ption per Cage frolU the Initiation of 
Injections to Weaning of the Pups. Food and water consumption per cage 
per gram maternal weight are given beginning with the first injection 
day (D-6) and continuing through day 21. Water is expressed in m.l/g 
body weight and food is given as g / g body weight. 
Group DAMS SC DC 
Day Water Food W-ater Food Water Food 
mJ/g gig ml/g gig ml/g gig 
D-6 .25+.07 . 13+. 04 .23+.06 · 14+.02 .25+.06 · 16+.03 
D-5 .23+.05 .15+.05 • 22 +. 04 .15+.03 .24+.03 · 14+. 04 
D-4 .22+.04 .16+.04 .21+.04 .17+.05 .21+.03 .19+.04 
D-3 .23+.04 .16+.04 .21+.05 .16+.03 .22+.02 .17+.03 
D-2 · ZI+. 04 .15+.03 .17+.04 .13+.05 .18+.03 · 14+. 03 
D-1 .26+.05 .19+.05 .22+.06 .18+.10 · 2Z+. 05 .13+.02 
Delivery • 34+. 07 
-
.25+.06 .29+.05 .21+.06 · 34+. 09 · 23+. 04 
3 .41+.06 .37+.08 .32+. 07 · 28+. 06 .31+.09 .25+.07 
7 .47+.11 .37+.12 .44+.10 · 36+. 07 .43+.05 .34+. 09 
14 · 68+. 09 .40+.10 .53+.20 · 34+. 05 .65+.06 .36+.10 
21 .49+.16 . 16+. 03 .30+.01 · 17 +. 04 · 39+. 08 .18+.04 
Mean + S. D. M. 
Table IV. Food and Water Consum.ption per Cage from the Initiation of Injections to Weaning of 
the Pups. N 
~ 
fl' 
Pup Weights - Figure III. and Table II. of the Appendix show the pup 
body weights for the three groups in the biochemical study. Using 
the two-tailed t-test, there was no statistical difference on any gi ven 
day, but there was a group difference (p < .025) and a group by time 
interaction (p < .01). Since the differences were only noted using 
the least squares analysis, the group and group by time changes 
would indicate that the pattern of weight gain over time for the three 
groups differed enough to produce statistical changes. 
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A statistical difference in weight was also noted by sex (p < • O~S). 
The females weighed the same as the males at birth but were smaller 
than the males at day 30 in all groups. 
The weights of the pups used in the psychological studies were 
tabulated separately to check for any effects of handling (Table V. ). 
At all ti.mes the DAMS pups weighed statistically les s than the other 
two groups with the exception of days 17 and 18. On day 30 the SC pups 
also weighed less than the DC group. Whether the statistical differences 
were due to handling or a combination of handling stress and other 
factors is unknown. The weight difference could be due to a reduction 
in ITlaternal care and food supply due to the litter size. It could be that 
the slYlaller litter size accentuated any difference in weight caused by 
the drug or the injection. This effect would then have been obscured 
in the larger litters of the biochem.ical studies. 
In Table V. a plateau in weight gain from appr.oxim.ately day 16 
to day 19 can be seen. It began just after the eyes opened and continued 
Figure III. Body Weights in GralnS from Birth to 30 Days of Age for 
Pups Used in the Biochemical Study. The body weights for the ex-
perirrlental (DAMS) and the 2 control groups (SC and DC) are given 
for each experimental day from birth to 30 days of age. The litters 









8 '.' r-,.,..... 
o 3 7 14 21 30 " 
TIME IN DAYS 
Figure III. Body Weights in Gram.s from Birth to 30 Days 
of Age for Pups Used in the Biochemical Study. 
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Table V. Body Weights in Grams from 12 to 30 Days of Age for Pups 
Used in the Psychological Study. The body weights for the 3 groups of 
animals are given beginning with the first day of experimental work and 
continuing through day 30. The pups were tested on days 12, 15, 18, 
21, and 30 on the jiggle platform and on days 13, 16, 19, 22, and 31 
in the open field maze. The litters were culled to 4 pups at delivery. 
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Group DAMS SC UC 
Day 
12 6. 7 + O. 8 ~::: ~::: * ( 24) 7.2+0.8(20) 7.7+1.2(21) 
........ "" ........ ~ 
13 7 . 2 + O. 8 "I~ 'I~ "I' ( 24) 7. 8+0. 9(20) 8.3+1.3(21) 
... ,-' -..''''''' ..... f''' 
14 7. 7+0. S .. ·"I'· .... · (24) 8. 2+0. 9(20) 8. 7 + 1. 3 (21) 
,1 ... '-'J- .... f ... 
8.6+0.9(19) 15 8. 3 +0. 8 .. ·' .. · .... , .. (22) 9.2+1.4(21) 
.. 1# 
16 8.6+0.9""(22) 8.8+0.9(19) 9.4+1.3(21) 
17 8 . 8 +0. 8 (2 2 ) 9. 1 +0. 4 (19) 9.5+1.4(21) 
18 8 .. 9+0.9(22) 9. 0+0. 9(19) 9 .. 6 + 1. 3 (21) 
19 8.9+0.9*(22) 9. 0+1.0(19) 9. 7 + 1. 4(21) 
20 9. 4+0. 9>::: (22) 9. 4+ 1. 1 (1 9) 10.2+1.4(21) 
21 9. 9+0. 9'* (22) 9. 9+0. 9( 19) 10. 8 + 1. 6 (21) 
30 15. 9+0.8*>:(20) 16. 0+2. 1 *(17) 17.8+2.7(19) 
Mean + S. D. M. (N) >:( (p < ? • 05) 
*):( (p < • 02) 
... t..>,;>", ( --... , ..... p < • 01) 
Table V. Body Weights in Grams from 12 to 30 Days of Age for Pups 
Used in the Psychological Study. 
until just before weaning. The pups might be requiring more milk than 
the ITlother can supply and the pups are gradually starting to eat and 
drink for thernselves. The pups did continue to nurse until weaned 
and then Inaintained another, shorter-term plateau, as previously 
ITlentioned, just after weaning. 
Brain Weights - Pup brain weights (Fig. IV. , also Appendix -
Table III.), unlike pup body weights I show no group differences. 
The brain weight gain pattern for the groups did show a group by 
tirne interaction (p < .005). Initially the 3 groups had a brain 
weight approximately the sarne, but by day 7 the DC brain weights 
were higher than the other 2 groups. This continued until day 21 when 
the pattern reversed. At day 30 the order from. high to low was SC t 
DAMS, and DC. This is the sam.e order as the body weights at day 30. 
Sex als 0 affected the b rain weight (p < • 005), but the re was 
no time by s ex effect. 
Norepinephrine - The brain NE values are given in Fig. V. and Table 
IV. of the Appendix. Both NE and DA are expres sed on a per brain 
basis to exclude any effects due to changes in total cell number or 
changes in the number of cells containing the m.onoam.ines (88). The 
NE levels were also calculated in terms of per graIn brain J however, 
and are listed in Table V. of the Appendix. 
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In Fig. V. a statistically significant, low level of NE can be seen 
in the DAMS at day 0 as compared with the DC. This is not unexpected 
Figure IV. Brain Weights in Grams from Birth to 30 Days of Age for 
Pups Used in the Biochemical Study. The brains, minus the olfactory 
bulbs, were weighed and frozen until assayed. The values are given 
in grams wet weight. There was no statistical difference on any given 
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Figure IV. Brain Weights in Grams £roITl Birth to 30 Days 
of Age for Pups Used in the Biochern.ical Study. 
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Figure V. Nanograms of Norepinephrine per Brain. The norepineph-
rine per brain for the 3 groups studied showed an initially low level 
and gradually increased with time. The 'statistical differences were 
obtained by comparing the DAMS with the UC and the SC with the UC. 
There is also a significant difference (p < .01) between the DAMS 





~ - ~l 
~ ~1 









Day 21 Day 30 
Figure V. Nanograms of Norepinephrine per Brain. 
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since prolonged trcat.m.ent with amphetamine depletes NE (42, 94) and 
suggests that there was some placental transfer of amphetamine. The 
levels are approximately normal by day 3. The SC group is also lower 
than DC group at day 0 but not statistically so. All three groups show 
an increase from. 0 to 30 days (p < .01). On day 21 the SC group and 
on day 30 both the DAMS and the SC groups show a significant increase 
above UC values, with the DAMS showing a level roughly twice that of 
the DC values (p < .001) and statistically higher (p < .001) than the 
SC values also. The group differences were significant at the p < .01 
level and there was a group by tim.e interaction at the p < • 01 level. 
The values of NE/g brain parallel those of NE/brain. The 
changes in NE/brain or in NE/g brain do not parallel the weight gain 
pattern for the three groups except at days 0 and 7. This trend is 
certainly not followed at day 30 when the levels of NE in the DAMS 
group are much higher than the SC or DC and the SC brains are larger 
than DAMS and UC. 
Doparnine - The DA values (Fig. VI., also Appendix - Table VI. ) 
parallel those of NE except there is apparently no initially low level 
in the DA1v1S group. A slight but nonsignificant decrease occurs on 
day 3 for the DAMS group. This assay is not so sensitive (8 ng) as 
the NE assay (2 ng), thus the greater variation at low levels. On day 
31 
21 the SC and on day 30 both the DAMS and the SC groups have levels of 
DA significantly above UC levels. The DAMS levels are not statistically 
higher than SC at day 30 however. 
Figure VI. .Nanograms of Dopamine per Brain. The changes in levels 
of dopaITline over tim.e parallel.ed those of norepinephrine; however, the 
levels per brain at any given time were higher than those of norepineph-
rine. The DAMS and the SC were compared with the UC group to obtain 
statistical differences. There was no statistical difference between the 
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Figure VI. NanogralTI.s of Dopam.ine per Brain. 
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The levels of DA/brain are listed in the Appendix - Table VII. 
The change with ti,lTIC is significant at the p < • 01 level. The group 
effect is significant at the p < .05 level. The values per gra.m. brain 
parallel those of DA /brain except the increase over time in the DAMS 
group is ITlore exaggerated. 
Psychological Studies - The jiggle platforrn activity scores showed 
extreme variance at all times making analysis difficult using the raw 
scores. The medians, a measure of the central tendency of the 
aniITlals, for the days studied: 12,' 15, 18, 211 and 30, indicated that 
the DAMS activity level was lower than SC and UC on days 12-18. The 
DAMS .m.edian rose to a level higher than UC but lower than SC on day 
21, and by day 30 the activity level for the DAMS anim.als had risen to 
a value higher than SC and UC. This trend was not substantiated by the 
t-test due to the wide variance in the raw score values. 
The anim.als used in the psychological testing consisted of 2 
sets of animals born 2 weeks apart and each set consisted of DAMS, 
SC, and UC anim.als. Since the DAMS, SC,and DC ani.m.als from a set 
were all run on the same day for a given experimental day, any varia-
tion due to the day to day changes in the jiggle platform. could be 
eliminated by putting the DAMS and SC values in term.s of the mean of 
the DC and expres sing the value as a percent of the mean of the DC for 
the particular ti.m.e period (Fig. VII., also Appendix - Table VIII. ). 
This yielded a group effect significant at the p < .01 level. There was 
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females were higher than the values for the males within a group, how-
ever, and the SC values were higher than DAMS values at all times. 
The DAMS values were lower than UC levels at days 15 and 18. 
Analysis of the open field activity revealed no group or sex 
effects with the least squares analysis. The t-test did reveal a dif-
ference at day 22 when DAMS levels were higher than SC or UC 
(Table VI.). The levels of activity did increase over time indicating 
the Inicc became more active with age. How long this trend of in-
creased activity continued was undetermined. 
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Table VI. Open Field Maze Scores. The open field scores for the 3 
groups gave no group or sex effect. The anim.als did become more 
active with age, particularly between days 16 and 19. This is the 
time when their visual acuity has increased and the pups can see to 
move about. On day 22 the DAMS pups did show a statistical increase 
in activity over the UC group, but at no other time did such a difference 
occur. 
36a 
Treatluent DAMS SC UC 
Day 
13 29+18 34+24 32+23 
16 58+49 59+31 42+50 
19 130+75 121 +56 135+55 
.. I,. 
22 159+34'''- 144+34 131+17 
31 165+34 178 +32 161+35 
N = 12 N = 10 N = 12 
Mean + S. D. M. 
Table VI. Open Field Maze Scores. 
/ 
CONCLUSIONS 
D-Amphetamine sulfate (5 mg/kg) given to pregnant C57BL/6J 
mice during the last 6 days of pregnancy caused a decreased weight 
gain beginning 3 days after the initiation of injections and continuing 
for at least 3 days post partum. Food and water consumption per gram 
did not differ among the 3 groups of mothers at any time from the be-
ginning of injections through weaning of the pups. At delivery the 
litter size was no different for the DAMS, SC, and UC. The offspring 
had no difference in body or brain weight at birth or at any other time 
in development. The DAMS and SC groups did show a more rapid 
increase in brain and body weight in early development, especially 
between days 7 and 14, than the UC. After 14 days the weight gain per 
day slowed down and did not differ between groups. The possible effects 
of the amphetamine or the injection stress on the developing hypo-
thalamus and pituitary gland could have induced the pattern of weight 
change. Amphetamine does affect areas of the hypothalamus and 
midbrain that control the secretion of neuroendocrine releasing factors 
for corticotropin and growth hormore (9, 17 t 107). The DAMS pups 
used in the psychological studies did have a mean body weight lower than 
that of the UC. The smaller litter size utilized in the psychological 
study could possibly have caused reduced maternal care and hence, 
sn"lallcr pups. The DAMS pups in the psychological study did not differ 
significantly in body weight froIn the DAMS pups in the biochemical 
study, however. Other studies have shown that D-am.phetam.ine sulfate 
did not affect litter size or pup weight (26, 30, 41, 53). A sex effect 
\vas found but there was no statistical difference in brain or body weight 
by sex at any tiIne. A weight difference by sex has been noted in other 
studies with the behavioral performance dependent on the sex of the 
a nirnal (26, 45) . 
In the present study it was found that the NE levels were higher 
and the DA levels were lower in the UC mice at day 0 than in the study 
by Agrawal and Hirn.wich (I). The levels of both catecholam.ines in-
creased steadily through day 30. At day 30 the NE levels reznained 
higher and the DA rell1.ained lower than the levels given by Agrawal 
and Hirnwich (1). It is difficult to compare the values obtained in this 
study with the values reported by other workers since the tiIne periods 
chosen are often not the same and the strain of Inouse used is not 
always specified. 
While no values for catecholaIlline levels in young C57BL/6J 
nlice have been reported, levels of NE of about 385 ng/g brain have 
38 
been reported for adult ll1.ale C57BL/6J Inice 70 to 100 days of age (81). 
Boggan and Seiden (19) have found NE levels of 315 ng/g brain in 30 day 
old DBA/2 !nice and 390 ng/g brain in 27 day old DBA/l mice. They also 
found DA levels of about 617 ng/g in DBA/Z mice and 1000 ng/g brain in 
DBA/l nUce. These values compare favorably"with the 325 ng/g and the 
39 
730 ng/g brain for the NE and DA, respectively, found in the 30 day UC 
anin.lals in. this stud Y . 
The low NE levels at day 0 in the DAMS group suggests that 
SOITlC placental transfer of amphetamine or its m.etabolites did occur. 
Radioautographic studies using other psychoactive drugs have demon-
,I .. 
strated the placental transfer of such drugs"", so it is asswned some 
forn.'1 of the alTIphetaITline is transferred in this case. The low levels 
of DA at day 0 agree with SOale reports on the effects of am.pheta.mine 
(43: 89, 112). The effect on the catecholamines is a dose dependent 
response with BOlTIe disagreement as to the dose-response levels. Low 
levels of amphetamine cause an increase in NE and DA levels while 
higher doses cause depletion. The doses that cause the modifications 
vary according to the species and the assay procedure (63, 112). 
Coyle and Axelrod reported that the NE uptake and the increase 
in endogenous NE begin on days 17 and 18 of gestation (31). This is 
during the time of the injections of drug and vehicle in this study. The 
day 0 levels of NE suggest that the drug has lowered endogenous NE 
levels. This could be due to a modification of uptake and/or to in-
creased release. Amphetamine is known to block uptake of NE in 
adult organisITls (42, 51, 83, 94, 112) and also to cause synaptic re-
lease of NE and DA (51, 94). If the am.phetaITline had been taken up 
by the neurons or at least had blocked the uptake or increased the 
';:~w. J. Waddell 1971: personal cornm.unication. 
release of the catecholamine, the regulation of tyrosine hydroxylase 
could have been lUodified. This enzym.e is regulated by feedback inhi-
bition by NE. Tyrosine hydroxylase levels also appear to be subject 
to genetic control (11). NE causes a repression of enzyme synthesis. 
Shoemaker and Wurtm.an report that rats whose dams received a 
40 
protein deficient diet during pregnancy had decreased NE and DA levels 
and increased tyrosine hydroxylase at day 24 (88). The lowered levels 
of NE at birth could cause not only increased levels of tyrosine hydroxy-
lase but also increased tyrosine hydroxylase activity_ This increased 
activity could lead to an overshoot of catecholamine levels by day 21 
and 30. That increased catecholamine levels do not appear until 21 to 
30 days of age could be due to furthe r regulation of NE biosynthesis by 
dopamine - a -hydroxylase. Modified levels of dopaInine - a -hydroxylase 
in the developing catecholamine storage vesicles could convert exag-
gerated all'lounts of DA to NE. Chronic reserpine treatrnent can cause 
the levels of dopamine- a -hydroxylase to increase in sympathetic 
ganglia. This increase can be blocked by inhibition of protein syn-
thesis (11). 
The total number of adrenergic neurons could also be increased. 
No work was done to ascertain whether there was an increased cell 
nwnber in the brain. The turnover rate for NE and DA was also not 
determined. It is also possible that there were no enzym.e rnodifications, 
but a change in the catecholamine turnover rate occurred. There could 
also have been an increased nuIllber of vesicles in each neuron with 
41 
subsequent increased levels of NE and DA. The atnphetarnine could 
cause an increased nUlnber of the amine storage vesicles to be formed 
and transported down the axon. 
The increase in catecholamine levels at 21 and 30 days is also 
consistent with increased axonal downflow of monoamine storage 
vesicles with a life span of 3 to 4 weeks that has been reported in 
rats after reserpine treattnent (48). The 30 day time course is also 
consistent with rates of slow axoplasrrric downflow of the storage 
vesicles (14). 
The elevated levels of NE and DA in the DAMS and SC groups 
at day 30 could have been due to prenatal stress since both groups 
were elevated above control. Footshock administered to a female rat 
during pregnancy resulted in an increased NE turnover in the telen-
cephalon-diencephalon area of the brain at 40 to 45 days of age. In-
creased NE levels were also noted in the brain steIn-mesencephalon 
area (53). It seems that the stress of the injections to the mother 
caused a change in catecholarnine levels on the young pup. Arnph~t­
anline enhanced this stress effect. The .mechanism for the stress 
effect is unknown and likewise it is unknown whether amphetamine 
uses the same or a different mechanism to further increase the stress 
effect on brain catecholarn.ine levels. 
Activity studies were undertaken to determine if changes in 
brain catecholamine levels would produce tneasurable changes in 
locom.otor activity.. The jiggle platforIll. rneasured generalized 
activity and the open field study measured ~ocornotor activity. 
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The variance at all times and in all groups on the jiggle platform 
prevented the raw data being used as a reliable .measure. The central 
tendency of the groups was consistent with changes in catecholamines 
but the correlation was not statistical. Day 30 jiggle platform. scores 
would have been significantly higher (p < .05) than DC if the single 
high value out of 12 animals in the DC group were dropped. This one 
high value was almost twice the value of the second highest score and 
the remainder of the scores were closely grouped around the second 
highest value. Further work in this lab has shown that the offspring 
of mice who were injected for longer periods of time with amphetamine 
had activity levels higher than UC (p < .025) when tested on the jiggle 
,f", 
platform at 34 days of age "j~. 
When the data is presented as the percent of the mean of UC 
values, the resultant graph resembles an habituation curve. The 
values are initially high and gradually decrease then start to rise again. 
The activity levels of the SC males and fem.ales on day 30 were lower 
than their initial levels on day 12, but the DAMS .males and females 
had values higher than their initial scores. This could have been due 
to the design of the experiment. The anim.als were not handled from 
day 22 to day 30 except for weighing. The DAMS animals could have 
been more sensitive to the trauma of the jiggle platform and the de-
creased handling from day 22 to day 30 e:rnphasized this sensitivity. 
;;:~L. D. Middaugh 1971: personal corrununication. 
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The reverse could be true with the SC animals being less sensitive. 
Overall the injection stress could have increased activity levels and 
the amphetamine antagonized the stress effect. 
The correlation of activity with NE and DA levels is obscure. 
The SC values were higher than but parallel to the DAMS at all times. 
On days 21 and 30 for SC and day 30 for DAMS when there was a 
statistically significant difference in NE and DA levels, there was only 
a marginally significant difference in the activity levels. At day 30 
when the DAMS catecholamine values are elevated above the SC values, 
the SC activity levels were still higher than DAMS. If levels in specific 
areas of the brain were obtained, the relation of catecholamine levels 
to jiggle activity might be clarified. 
The open field scores were alrnost identical initially and in-
creas ed over tirn.e. The scores increased greatly from day 16 to 
day 19. During this time the pups f visual acuity increased and their 
exploratory behavior also increased. Only on day 22 is there a 
statistically significant diffe re nce in the scores. At that time both 
the DAMS and the SC were higher than the VC. Clark et ale (26) 
administered 1 rng /kg of D-arnphetarnine sulfate to pregnant rats from 
days 12 through 15 of gestation. The offspring were tested at various 
times in an open field activity box. The offspring of the arnpheta.rnine 
}])~Jr9S.l..? E2~ }~:y _~~_t!:vitJ scores in the 0yen field test 21 days after 
birth when compared to saline controls. Since there is an anomalous 
dosage effect of amphetamine on catecholamine levels, the higher activ-
ity levels with 5 rng/kg in our study is not unexpected. 
The open field values on day 30 could have been influenced by 
the cxperilTIcntal design as were the jiggle platforll1. tests. After a 
week of little handling, the se and ue values increased above those 
of day 22 while the DAMS values changed very little. The jiggle plat-
form and the open field are measures of different types of activity and 
therefore differing results are not unexpected. 
It has been determined that aInphetamine caused a decreased 
maternal weight gain, but had no effect on food and water consump-
tion, litter size, and pup brain and body weights. There are in-
creased NE and DA levels at day 30. Behavior is also modified. The 
increased brain catecholamine levels could be due to direct action of 
arnpheta.m.ine or the injection stress on the biosynthesis of the 
catecholantines and induction of the behavioral changes. The increase 
could be due also to a latent effect on the adrenal medulla to release 
epinephrine and thereby change the brain catecholam.ine levels and 
modify behavior (15, 17). 
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Regardless of the Ill.echanisrn by which the changes occurred, 
this research has clearly dem.onstrated that the prenatal administration 
of the central nervous system stimulant, amphetamine, has produced a 
pronounced and significant change in the brain - a doubling of NE and of 
DA at 30 days. Saline control animals suggest that at least part of the 
effect is due to stres s. Activity indices suggest that the changes in 
catecholarnines rnay produce behavioral changes in these animals. 
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1 Day 14 Days 
NE DA NE DA 
n /brain) (n /brain) (n /brain) (n /brain) 
236 621 219 661 
248 573 227 623 
229 654 240 602 
225 642 222 612 
Table I. The Effects of Freezing on Brain Catecholamine Levels. 
Treatment DAMS SC UC 
Day 
0 1. 27 +0. 09( 40) 1. 27 +0. 13 (40) 1. 32+0. 10(38) 
3 1.85+0.09(29) 2. 1 0 +0. 4 7 ( 28) 2. 14+0. 26 (35 ) 
7 3.96+0.59(16) 4. 14 +0. 4 7 ( 15 ) 4. 05 +0. 97 ( 1 5 ) 
14 8. 33 +0. 39 ( 14) 7. 99+0. 94( 1 0) 7.47+1.32(12) 
21 10.00+1.1S(11) 10. 1 7 + 1. 45 ( 10) 9. 79 + 1. 1 9( 14) 
30 16.77+1.49(11) 17.53+2. 58(S} 16.22+2.76(18) 
Mean + S. D. M. (N) 
Table II. Body Weights in Gram.s from Birth to 30 Days of Age for 
Pups Used in the Biochem.ical Study. 
59 
Treatment DAMS SC UC 
Da 
0 .086 .087 .090 
3 . 130 . 137 .139 
7 .236 .222 .246 
14 .376 .382 .373 
21 .399 .400 .399 
30 .419 .423 . 412 
Table III. Brain Weights in Grams from Birth to 30 Days of Age 
for Pups Used in the Biochemical Study. 
60 
61 
Treatnlent DAMS SC UC 
I 
Day I 
,t ....... , .. 
0 5. 2 2 + 1. 1 2 'I" ~I" ( 5 ) 9.81+1.79(8) 11.68+1.62(5) 
3 19.12+7.72(7) 23. 8 9 +8. 8 9 ( 6 ) 22.48+5.91(7) 
7 36. 5 9 + 1 3. 3.0 ( 4) 36.30+2. II(5) 41. 88+7.54(6) 
14 75. 8 1 +9. 0 1 ( 6 ) 73. 5 0 +5. 07 ( 3 ) 87.34+10.41(5) 
.. I" 
21 116.28+14.89(6) 130. 95+3. 35",1" (5) 96.65+19.03(6) 
290.41+54.33**(6) 
.. f", 
30 1 78. 8 4 +5 1 • 40 ..... ( 6 ) 133. 55 +47. 45 (12) 
Mean + S. D. M. (N) *(p < • 01) 
....r .... ,t.-. 
~I""'" (p < • 001) 
Table IV. Nanograms of Norepinephrine per Brain. 
Table V. Nanograms of Norepinephrine per Gram Brain. The levels 
of norepinephrine per gram wet weight of brain increased gradually 
with time. The group effect was significant at the p < • 05 level and 
the group by time interaction was significant at the p < • 01 level. 
62a 
Treatment DP .. MS SC DC 
Day 
0 62.50 115.20 133.34 
3 144. 31 170.30 158.68 
7 157. 48 161.82 175.24 
14 202.71 195.80 235.27 
21 294.02 328.72 242.42 
30 650.88 431.17 324.99 
Table V. Nanogra:ms of Norepinephrine per Gram Brain. 
63 
Treatment DAMS SC UC 
~ 
0 18.93+9.9 1 (5) 12.34+5.91(8) 14. 75 +6. 89 (4) 
3 13.91+11.21(7) 23.59+10.28(6) 2 1. 3 7 +6. 5 1 ( 6 ) 
7 I 45.80+18.70(4) 49. 32 +6. 80(5) 61.46+14.63(6) 
14 1167 • 07+20.42(6) 132.00+15.59(3) 178.76+28.40(5) 
.... 1, ...... , ............ 
21 288.23+80.65(6) 3 74. 8 9 + 1 5. 6 5 ~I' ~I"I'( 5 ) 454.69+92.08(6) 
30 5 5 8. 2 8 + 1 5 8. 7 5 ~:~ :::~ {6 ) 454.69+92.08:::\6 ) 301.61+136.60(12) 
Mean + S. D. M. (N) ~:, (p < • 05) 
):~ ~:~ ( p < • 0 1 ) 
... 1 ......... , ~ .... 
~'''I "( P < • 0 0 1 ) 
Table VI. Nanograms of Dopamine per Brain. 
Table VII. Nanograms of Dopamine per Gram Brain. The levels of 
dopamine per gram wet weight of brain follow the same pattern as 
those of the whole brain. They are also parallel to but higher than the 
levels of norepinephrine per gram brain. The group effect was sig-
nificant at the p < • 05 level and the group by time interaction was 
significant at the p < • 01 level. 
64a 
~c }·l'~~ltn1.C nt DAMS SC DC 
Day 
0 223.93 143.21 162.99 
3 103.24 168.02 155.36 
7 197.51 218.71 256.57 
14 445.38 349.67 480.00 
21 727.19 940.52 634.28 
30 1338.14 1095.32 730. 11 
Table VII. Nanograms of Dopamine per Gram Brain. 
65 
Treatment DAMS sc 
Sex Male Female Male Female 
Day 
12 123.0 126.7 149.0 163.3 
15 95.8 99. 5 130. 1 144.4 
118 I 93. 5 97.2 112.4 126.6 
I 
I 
121 ! 107. 1 110. 8 113. 9 128.2 
130 131.2 134.8 136. 5 150.8 
Table VIII. Jiggle Platform Scores. 
ERRATA 
Page 37, line 17. hormone. 
Page 63. day 21, UC. 254.69+92.08(6). - , 
Page 2a. 3-methoxydopamine should be 3-0-methyl dopamine. 
